The Group's principal activity is to discover and develop therapeutic vaccines. The Group develops gene-based vaccines used in treatment of cancer and infectious diseases. The Group follows three different strategies. The Group develops vaccines and partners with pharmaceutical companies for further development. The Group also independently develops and commercializes vaccines for certain special markets. The third strategy is to license vector technologies to companies with proprietary genes for short and medium term revenues. The Group markets the products under the brand names MYoDys, TG 4010, TG 4001, TG 1042 and TG 4040. The Group operates mainly in France.
Alacra Alerts:
Receive alerts on the latest reports on Transgene
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
